Cart
This product is not clubbable with other items in cart. Please remove this or other items to proceed further.
Deleting

No Items In Cart
At the 2013 Drug Delivery Partnership conference, West’s Bart Burgess partnered with Peter Krulevitch, Ph.D., Engineering Director, Packaging, Devices & Delivery, Janssen Pharmaceutical Companies of Johnson & Johnson to discuss West and Janssen’s unique partnership. Together, West and Janssen are developing the SelfDoseTM injector platform technology.*
The partnership began as an effort to meet patient needs with a simple, friendly self-administration device that would deliver Janssen biologic drug products. The product would need a reliable design that would be compatible with Janssen’s fill/finish infrastructure and easy to use for a range of patients.
Janssen has partnered with West to develop and manufacture the new SelfDose Injector Technology , an easy-to-use system designed for subcutaneous injection.
*For investigational use only for our pharmaceutical and biotechnology development partners; SelfDose [TM] has not been cleared or approved by the FDA as a standalone product.
SelfDose™ is a trademark of West Pharmaceutical Services, Inc., in the United States and other jurisdictions. West seeks partners for its SelfDose™ injector technology platform. This platform is intended to be used as an integrated system with drug filling and final assembly completed by the pharmaceutical/biotechnology company.